AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo

Investigational New Drugs

Volumn 29, Issue 4, 2011, Pages 554-561

  Torres, Mylin A ^a,b,d   Raju, Uma ^b   Molkentine, David ^b   Riesterer, Oliver ^b,c   Milas, Luka ^b   Ang, K Kian ^b  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AC480; Head and neck squamous cell carcinoma cells; Pan Her inhibitor; Radiation

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; AC 480; CYCLIN D; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H2AX; KU ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; GAMMA RADIATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARBAMATES; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HISTONES; HUMANS; IMMUNOPRECIPITATION; MALE; MICE; MICE, NUDE; RADIATION TOLERANCE; RADIATION, IONIZING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959743541     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9389-3     Document Type: Article

References (31)

1. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5:2884-2890 (Pubitemid 29493967)
2. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356 (Pubitemid 36025259)
3. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940 (Pubitemid 29186168)
4. Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174
5. Milas L, Akimoto T, Hunter NR, Mason KA, Buchmiller L, Yamakawa M et al (2002) Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 52:514-521 (Pubitemid 34170856)
6. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD et al (1997) Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15:1191-1197 (Pubitemid 27429622)
7. Schmidt-Ullrich RK, Valerie K, Fogleman PB, Walters J (1996) Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145:81-85 (Pubitemid 26006178)
8. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE (1997) Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5:180-186 (Pubitemid 27426395)
9. Liang K, Ang KK, Milas L, Hunter N, Fan Z (2003) The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57:246-254 (Pubitemid 36959763)
10. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L et al (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182-31189 (Pubitemid 41291855)
11. Dittmann KH, Mayer C, Ohneseit PA, Raju U, Andratschke NH, Milas L et al (2008) Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys 70:203-212 (Pubitemid 350251053)
12. Dittmann K, Mayer C, Rodemann HP (2005) Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76:157-161 (Pubitemid 41725442)
13. Walker F, Zhang HH, Burgess AW (2007) Identification of a novel EGF-sensitive cell cycle checkpoint. Exp Cell Res 313:511-526 (Pubitemid 46186303)
14. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J et al (2001) Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61:6500-6510 (Pubitemid 32783257)
15. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM (2004) Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64:5355-5362 (Pubitemid 39006556)
16. Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966-971 (Pubitemid 38221157)
17. Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M et al (2007) Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67:568-572 (Pubitemid 46108328)
18. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K et al (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708
19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (Pubitemid 43209104)
20. Beckhardt RN, Kiyokawa N, Xi L, Liu TJ, Hung MC, el-Naggar AK et al (1995) HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 121:1265-1270
21. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G (2007) Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 29:655-664 (Pubitemid 47168236)
22. Ekberg T, Nestor M, Engstrom M, Nordgren H, Wester K, Carlsson J et al (2005) Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 26:1177-1185
23. Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang H et al (2006) Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 12:6186-6193 (Pubitemid 44703785)
24. Raju U, Gumin GJ, Noel F, Tofilon PJ (1998) IkappaBalpha degradation is not a requirement for the X-ray-induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumour cells. Int J Radiat Biol 74:617-624 (Pubitemid 28539461)
25. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D et al (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67:7212-7222 (Pubitemid 47206549)
26. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N et al (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198-3208 (Pubitemid 38581423)
27. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D et al (2005) The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 65:692-697 (Pubitemid 40216423)
28. Corin I, Di Giacomo MC, Lastella P, Bagnulo R, Guanti G, Simone C (2006) Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors. Cancer Biol Ther 5:198-203 (Pubitemid 43327539)
29. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Florenes VA (2007) Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 110:1264-1271 (Pubitemid 47435597)
30. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566-1575 (Pubitemid 35315837)
31. Milne AN, Carvalho R, Jansen M, Kranenbarg EK, van de Velde CJ, Morsink FM et al (2008) Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival. J Clin Pathol 61:311-316 (Pubitemid 351354236)